IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial - Poll - MDSpire

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

At ARVO 2026, Arshad M. Khanani, MD, MA, FASRS, presented phase 2 data on vamikibart, an IL-6 inhibitor, in diabetic macular edema.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • Arshad M. Khanani, MD, MA, FASRS

  • May 1, 2026

  • 4 min

Share

Original Source(s)

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

  • by Arshad M. Khanani, MD, MA, FASRS, Arshad M. Khanani, MD, MA, FASRS

  • May 1, 2026

Related Content

ASC Growing Pains

Daniel Eisenstadt of Terramed Real Estate Solutions discusses factors that contribute to limited surgical capacity and what can be done about them.

  • May 1, 2026

  • 5 min
Advocacy Pays Off for ASCs

At the Outpatient Ophthalmic Surgery Society’s “OOSS Perspective 2026” symposium in Washington, DC, the organization's Washington counsel, Michael Romansky, JD, delivered an update on reimbursement, regulatory developments, and advocacy priorities affecting ophthalmic ambulatory surgery centers (ASCs).

Effectiveness of Manuka Honey Eye Drops for Alleviating Dry Eye Symptoms Post-Cataract Surgery: A Prospective Controlled Trial